Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• PI3K and CDK4/6 inhibitors are approved targeted therapies for advanced breast cancer.
• CDK4/6 inhibitors are more commonly utilized in clinical practice.
• The PI3K pathway is implicated in resistance mechanisms to CDK4/6 inhibitors.

Purpose of the Study:

• To discuss ongoing clinical trials investigating PI3K inhibitors.
• To explore novel drug combinations involving PI3K inhibitors.
• To evaluate the efficacy of combining PI3K inhibitors with CDK4/6 inhibitors.

Main Methods:

• Review of current clinical trials.
• Analysis of preclinical data linking PI3K pathway to CDK4/6 resistance.
• Discussion of emerging therapeutic strategies.

Main Results:

• Emerging data suggests potential for PI3K inhibitors in combination therapies.
• Combinations including PI3K inhibitors and CDK4/6 inhibitors are under investigation.
• These combinations aim to address resistance to CDK4/6 inhibitors.

Conclusions:

• Novel combinations of PI3K inhibitors, including with CDK4/6 inhibitors, show promise.
• Targeting the PI3K pathway may overcome resistance to CDK4/6 inhibitors in breast cancer.
• Further research and clinical trials are warranted to validate these findings.